Assessment of Brand Name Prescribing of Biologics (IRAS Ref. 226131)

A survey to evaluate the extent to which national recommendations on brand name prescribing of all biological DMARDS including biosimilars are used to manage rheumatological conditions within acute trusts in the UK are being complied with.

Complete the form below and the DSRU will contact you when the study begins. You do not have to participate in the study. It is your choice.

Enter your details

* Required fields